TY - JOUR
T1 - Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
AU - Imai, Masaki
AU - Iwatsuki-Horimoto, Kiyoko
AU - Hatta, Masato
AU - Loeber, Samantha
AU - Halfmann, Peter J.
AU - Nakajima, Noriko
AU - Watanabe, Tokiko
AU - Ujie, Michiko
AU - Takahashi, Kenta
AU - Ito, Mutsumi
AU - Yamada, Shinya
AU - Fan, Shufang
AU - Chiba, Shiho
AU - Kuroda, Makoto
AU - Guan, Lizheng
AU - Takada, Kosuke
AU - Armbrust, Tammy
AU - Balogh, Aaron
AU - Furusawa, Yuri
AU - Okuda, Moe
AU - Ueki, Hiroshi
AU - Yasuhara, Atsuhiro
AU - Sakai-Tagawa, Yuko
AU - Lopes, Tiago J.S.
AU - Kiso, Maki
AU - Yamayoshi, Seiya
AU - Kinoshita, Noriko
AU - Ohmagari, Norio
AU - Hattori, Shin Ichiro
AU - Takeda, Makoto
AU - Mitsuya, Hiroaki
AU - Krammer, Florian
AU - Suzuki, Tadaki
AU - Kawaoka, Yoshihiro
N1 - Funding Information:
ACKNOWLEDGMENTS. We thank Susan Watson for scientific editing. We also thank Yuko Sato along with Lin Schure, Ashlee McDonald, and Jarin Ryland at the Wisconsin Veterinary Diagnostic Laboratory for technical assistance. We are grateful to Jun Masumoto, Yuanzhong Li, Toshikazu Ban, and Koichi Yamada for help with generation of movies of micro-CT images. This research was supported by a Research Program on Emerging and Reemerging Infectious Diseases (Grants JP19fk0108112, JP19fk0108113, and JP19fk0108166), a Project Promoting Support for Drug Discovery (Grants JP20nk0101612, JP20nk0101614, and JP20nk0101603), the Japan Initiative for Global Research Network on Infectious Diseases (Grant JP19fm0108006), a Japan Program for Infectious Diseases Research and Infrastructure (Grant JP20wm0125002) from the Japan Agency for Medical Research and Development, and the National Institutes of Allergy and Infectious Diseases-funded Center for Research on Influenza Pathogenesis (Grant HHSN272201400008C).
Funding Information:
We thank Susan Watson for scientific editing. We also thank Yuko Sato along with Lin Schure, Ashlee McDonald, and Jarin Ryland at the Wisconsin Veterinary Diagnostic Laboratory for technical assistance. We are grateful to Jun Masumoto, Yuanzhong Li, Toshikazu Ban, and Koichi Yamada for help with generation of movies of micro-CT images. This research was supported by a Research Program on Emerging and Reemerging Infectious Diseases (Grants JP19fk0108112, JP19fk0108113, and JP19fk0108166), a Project Promoting Support for Drug Discovery (Grants JP20nk0101612, JP20nk0101614, and JP20nk0101603), the Japan Initiative for Global Research Network on Infectious Diseases (Grant JP19fm0108006), a Japan Program for Infectious Diseases Research and Infrastructure (Grant JP20wm0125002) from the Japan Agency for Medical Research and Development, and the National Institutes of Allergy and Infectious Diseases-funded Center for Research on Influenza Pathogenesis (Grant HHSN272201400008C).
Publisher Copyright:
© 2020 National Academy of Sciences. All rights reserved.
PY - 2020/7/14
Y1 - 2020/7/14
N2 - At the end of 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was detected in Wuhan, China, that spread rapidly around the world, with severe consequences for human health and the global economy. Here, we assessed the replicative ability and pathogenesis of SARS-CoV-2 isolates in Syrian hamsters. SARS-CoV-2 isolates replicated efficiently in the lungs of hamsters, causing severe pathological lung lesions following intranasal infection. In addition, microcomputed tomographic imaging revealed severe lung injury that shared characteristics with SARS-CoV-2-infected human lung, including severe, bilateral, peripherally distributed, multilobular ground glass opacity, and regions of lung consolidation. SARS-CoV-2-infected hamsters mounted neutralizing antibody responses and were protected against subsequent rechallenge with SARS-CoV-2. Moreover, passive transfer of convalescent serum to naïve hamsters efficiently suppressed the replication of the virus in the lungs even when the serum was administrated 2 d postinfection of the serum-treated hamsters. Collectively, these findings demonstrate that this Syrian hamster model will be useful for understanding SARS-CoV-2 pathogenesis and testing vaccines and antiviral drugs.
AB - At the end of 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was detected in Wuhan, China, that spread rapidly around the world, with severe consequences for human health and the global economy. Here, we assessed the replicative ability and pathogenesis of SARS-CoV-2 isolates in Syrian hamsters. SARS-CoV-2 isolates replicated efficiently in the lungs of hamsters, causing severe pathological lung lesions following intranasal infection. In addition, microcomputed tomographic imaging revealed severe lung injury that shared characteristics with SARS-CoV-2-infected human lung, including severe, bilateral, peripherally distributed, multilobular ground glass opacity, and regions of lung consolidation. SARS-CoV-2-infected hamsters mounted neutralizing antibody responses and were protected against subsequent rechallenge with SARS-CoV-2. Moreover, passive transfer of convalescent serum to naïve hamsters efficiently suppressed the replication of the virus in the lungs even when the serum was administrated 2 d postinfection of the serum-treated hamsters. Collectively, these findings demonstrate that this Syrian hamster model will be useful for understanding SARS-CoV-2 pathogenesis and testing vaccines and antiviral drugs.
KW - Countermeasure
KW - Infection
KW - SARS-CoV-2
KW - Syrian hamsters
UR - http://www.scopus.com/inward/record.url?scp=85088180274&partnerID=8YFLogxK
U2 - 10.1073/pnas.2009799117
DO - 10.1073/pnas.2009799117
M3 - Article
C2 - 32571934
AN - SCOPUS:85088180274
SN - 0027-8424
VL - 117
SP - 16587
EP - 16595
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 28
ER -